Abstract
Idiopathic calcium oxalate (CaOx) stones often develop attached to Randall’s plaque present on kidney papillary surfaces. Similar to the plaques formed during vascular calcification, Randall’s plaques consist of calcium phosphate crystals mixed with an organic matrix that is rich in proteins, such as inter-α-trypsin inhibitor, as well as lipids, and includes membrane-bound vesicles or exosomes, collagen fibres and other components of the extracellular matrix. Kidney tissue surrounding Randall’s plaques is associated with the presence of classically activated, pro-inflammatory macrophages (also termed M1) and downregulation of alternatively activated, anti-inflammatory macrophages (also termed M2). In animal models, crystal deposition in the kidneys has been associated with the production of reactive oxygen species, inflammasome activation and increased expression of molecules implicated in the inflammatory cascade, including osteopontin, matrix Gla protein and fetuin A (also known as α2-HS-glycoprotein). Many of these molecules, including osteopontin and matrix Gla protein, are well known inhibitors of vascular calcification. We propose that conditions of urine supersaturation promote kidney damage by inducing the production of reactive oxygen species and oxidative stress, and that the ensuing inflammatory immune response promotes Randall’s plaque initiation and calcium stone formation.
Key points
-
Randall’s plaques contain calcium phosphate (CaP) crystals mixed with membranous vesicles, collagen fibres and molecules involved in inflammatory responses, such as osteopontin and inter-α-trypsin inhibitor.
-
Calcification is modulated by many macromolecules that are generally involved in inflammation and osteogenesis; these molecules are also highly expressed in the kidneys of stone formers and in experimental models of nephrolithiasis.
-
Exposure of the kidney epithelium to crystals induces the production of reactive oxygen species that activate the NOD-, LRR- and pyrin domain-containing protein 3 inflammasome; inhibition of reactive oxygen species production and inflammasome activation reduces crystal deposition in animal models.
-
In rodent models, the inflammatory response to interstitial crystal deposition attracts macrophages, which leads to giant cell formation and may eventually result in crystal elimination.
-
Gene expression studies of kidneys from patients with kidney stones revealed pro-inflammatory macrophage gene signatures, whereas genes characteristic of anti-inflammatory macrophages were less abundant.
-
A better understanding of inflammasome activation and modulation of immune response to urine supersaturation and crystal deposition may provide new therapeutic options to reduce kidney stone recurrence.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Sorokin, I. et al. Epidemiology of stone disease across the world. World J. Urol. 35, 1301–1320 (2017).
Scales, C. D. Jr, Smith, A. C., Hanley, J. M., Saigal, C. S. & Urologic Diseases in America Project. Prevalence of kidney stones in the United States. Eur. Urol. 62, 160–165 (2012).
Xu, G. et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ 362, k1497 (2018).
Obligado, S. H. & Goldfarb, D. S. The association of nephrolithiasis with hypertension and obesity: a review. Am. J. Hypertens. 21, 257–264 (2008).
Daudon, M. & Jungers, P. Diabetes and nephrolithiasis. Curr. Diab. Rep. 7, 443–448 (2007).
West, B. et al. Metabolic syndrome and self-reported history of kidney stones: the National Health and Nutrition Examination Survey (NHANES III) 1988–1994. Am. J. Kidney Dis. 51, 741–747 (2008).
Strazzullo, P. et al. Past history of nephrolithiasis and incidence of hypertension in men: a reappraisal based on the results of the Olivetti Prospective Heart Study. Nephrol. Dial. Transplant. 16, 2232–2235 (2001).
Shoag, J., Halpern, J., Goldfarb, D. S. & Eisner, B. H. Risk of chronic and end stage kidney disease in patients with nephrolithiasis. J. Urol. 192, 1440–1445 (2014).
Keddis, M. T. & Rule, A. D. Nephrolithiasis and loss of kidney function. Curr. Opin. Nephrol. Hypertens. 22, 390–396 (2013).
Tiselius, H. G. Possibilities for preventing recurrent calcium stone formation: principles for the metabolic evaluation of patients with calcium stone disease. BJU Int. 88, 158–168 (2001).
Khan, S. R. et al. Kidney stones. Nat. Rev. Dis. Primers 2, 16008 (2016).
Uribarri, J., Oh, M. S. & Carroll, H. J. The first kidney stone. Ann. Intern. Med. 111, 1006–1009 (1989).
D’Costa, M. R. et al. Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: a prospective cohort study. J. Am. Soc. Nephrol. 30, 1251–1260 (2019).
Hyams, E. S. & Matlaga, B. R. Economic impact of urinary stones. Transl. Androl. Urol. 3, 278–283 (2014).
Antonelli, J. A., Maalouf, N. M., Pearle, M. S. & Lotan, Y. Use of the National Health and Nutrition Examination Survey to calculate the impact of obesity and diabetes on cost and prevalence of urolithiasis in 2030. Eur. Urol. 66, 724–729 (2014).
Ziemba, J. B. & Matlaga, B. R. Epidemiology and economics of nephrolithiasis. Investig. Clin. Urol. 58, 299–306 (2017).
Randall, A. The origin and growth of renal calculi. Ann. Surg. 105, 1009–1027 (1937).
Evan, A. P. et al. Randall’s plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J. Clin. Invest. 111, 607–616 (2003).
Khan, S. R. & Canales, B. K. Unified theory on the pathogenesis of Randall’s plaques and plugs. Urolithiasis 43, 109–123 (2015).
Khan, S. R., Finlayson, B. & Hackett, R. Renal papillary changes in patient with calcium oxalate lithiasis. Urology 23, 194–199 (1984).
Randall, A. Papillary pathology as a precursor of primary renal calculus. J. Urol. 44, 580–589 (1940).
Randall, A. Recent advances in knowledge relating to the formation, recognition and treatment of kidney calculi. Bull. N. Y. Acad. Med. 20, 473–484 (1944).
Khan, S. R. Histological aspects of the “fixed-particle” model of stone formation: animal studies. Urolithiasis 45, 75–87 (2017).
Moe, O. W., Pearle, M. S. & Sakhaee, K. Pharmacotherapy of urolithiasis: evidence from clinical trials. Kidney Int. 79, 385–392 (2011).
Mandel, N. S., Henderson, J. D. Jr, Hung, L. Y., Wille, D. F. & Wiessner, J. H. A porcine model of calcium oxalate kidney stone disease. J. Urol. 171, 1301–1303 (2004).
Penniston, K. L., Patel, S. R., Schwahn, D. J. & Nakada, S. Y. Studies using a porcine model: what insights into human calcium oxalate stone formation mechanisms has this model facilitated? Urolithiasis 45, 109–125 (2017).
Wu, X. R. Interstitial calcinosis in renal papillae of genetically engineered mouse models: relation to Randall’s plaques. Urolithiasis 43, 65–76 (2015).
Haggit, R. C. & Pitcock, J. A. Renal medullary calcification: a light and electron microscopic study. J. Urol. 106, 342–347 (1971).
Stoller, M. L., Low, R. K., Shami, G. S., McCormick, V. D. & Kerschmann, R. L. High resolution radiography of cadaveric kidneys: unraveling the mystery of Randall’s plaque formation. J. Urol. 156, 1263–1266 (1996).
Darves-Bornoz, A. et al. Renal papillary mapping and quantification of Randall’s plaque in pediatric calcium oxalate stone formers. J Endourol 33, 863–867 (2019).
Bouchireb, K. et al. Papillary stones with Randall’s plaques in children: clinicobiological features and outcome. Nephrol. Dial. Transplant. 27, 1529–1534 (2012).
Letavernier, E. et al. Demographics and characterization of 10,282 Randall plaque-related kidney stones: a new epidemic? Medicine 94, e566 (2015).
Khan, S. R., Rodriguez, D. E., Gower, L. B. & Monga, M. Association of Randall plaque with collagen fibers and membrane vesicles. J. Urol. 187, 1094–1100 (2012).
Evan, A. P. et al. Renal inter-alpha-trypsin inhibitor heavy chain 3 increases in calcium oxalate stone-forming patients. Kidney Int. 72, 1503–1511 (2007).
Evan, A., Lingeman, J., Coe, F. L. & Worcester, E. Randall’s plaque: pathogenesis and role in calcium oxalate nephrolithiasis. Kidney Int. 69, 1313–1318 (2006).
Carpentier, X. et al. High Zn content of Randall’s plaque: a mu-X-ray fluorescence investigation. J. Trace. Elem. Med. Biol. 25, 160–165 (2011).
Kuo, R. L. et al. Urine calcium and volume predict coverage of renal papilla by Randall’s plaque. Kidney Int. 64, 2150–2154 (2003).
Coe, F. L., Worcester, E. M. & Evan, A. P. Idiopathic hypercalciuria and formation of calcium renal stones. Nat. Rev. Nephrol. 12, 519 (2016).
Evan, A. P., Coe, F. L., Lingeman, J., Bledsoe, S. & Worcester, E. M. Randall’s plaque in stone formers originates in ascending thin limbs. Am. J. Physiol. Renal Physiol. 315, F1236–F1242 (2018).
Khan, S. R. Nephrocalcinosis in animal models with and without stones. Urol. Res. 38, 429–438 (2010).
Khan, S. R. Calcium oxalate crystal interaction with renal tubular epithelium, mechanism of crystal adhesion and its impact on stone development. Urol. Res. 23, 71–79 (1995).
de Bruijn, W. C. et al. Etiology of experimental calcium oxalate monohydrate nephrolithiasis in rats. Scanning Microsc. 8, 541–549; discussion 549–50 (1994).
Khan, S. R. Tubular cell surface events during nephrolithiasis. Curr. Opin. Urol. 7, 240–247 (1997).
Khan, S. R., Finlayson, B. & Hackett, R. L. Experimental calcium oxalate nephrolithiasis in the rat. Role of the renal papilla. Am. J. Pathol. 107, 59–69 (1982).
Khan, S. R., Glenton, P. A. & Byer, K. J. Modeling of hyperoxaluric calcium oxalate nephrolithiasis: experimental induction of hyperoxaluria by hydroxy-L-proline. Kidney Int. 70, 914–923 (2006).
Khan, S. R. & Glenton, P. A. Deposition of calcium phosphate and calcium oxalate crystals in the kidneys. J. Urol. 153, 811–817 (1995).
Nguyen, H. T. & Woodard, J. C. Intranephronic calculosis in rats: an ultrastructural study. Am. J. Pathol. 100, 39–56 (1980).
Chi, T. et al. A Drosophila model identifies a critical role for zinc in mineralization for kidney stone disease. PLoS One 10, e0124150 (2015).
Chen, Y. H. et al. Ethylene glycol induces calcium oxalate crystal deposition in Malpighian tubules: a Drosophila model for nephrolithiasis/urolithiasis. Kidney Int. 80, 369–377 (2011).
Khan, S. R. & Glenton, P. A. Calcium oxalate crystal deposition in kidneys of hypercalciuric mice with disrupted type IIa sodium-phosphate cotransporter. Am. J. Physiol. Renal Physiol. 294, F1109–F1115 (2008).
Chau, H., El-Maadawy, S., McKee, M. D. & Tenenhouse, H. S. Renal calcification in mice homozygous for the disrupted type IIa Na/Pi cotransporter gene Npt2. J. Bone Miner. Res. 18, 644–657 (2003).
Weinman, E. J. et al. Longitudinal study of urinary excretion of phosphate, calcium, and uric acid in mutant NHERF-1 null mice. Am. J. Physiol. Renal. Physiol. 290, F838–F843 (2006).
Letavernier, E. et al. ABCC6 deficiency promotes development of randall plaque. J. Am. Soc. Nephrol. 29, 2337–2347 (2018).
Li, Q., Chou, D. W., Price, T. P., Sundberg, J. P. & Uitto, J. Genetic modulation of nephrocalcinosis in mouse models of ectopic mineralization: the Abcc6(tm1Jfk) and Enpp1(asj) mutant mice. Lab. Invest. 94, 623–632 (2014).
Bouderlique, E. et al. Vitamin D and calcium supplementation accelerates Randall’s plaque formation in a murine model. Am. J. Pathol. 189, 2171–2180 (2019).
Pomozi, V. et al. Pyrophosphate supplementation prevents chronic and acute calcification in ABCC6-deficient mice. Am. J. Pathol. 187, 1258–1272 (2017).
Blazquez-Medela, A. M. et al. ABCC6 deficiency is associated with activation of BMP signaling in liver and kidney. FEBS Open Bio. 5, 257–263 (2015).
Mo, L. et al. Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am. J. Physiol. Renal Physiol. 293, F1935–F1943 (2007).
Khan, S. R. & Kok, D. J. Modulators of urinary stone formation. Front. Biosci. 9, 1450–1482 (2004).
Fleisch, H. & Bisaz, S. Mechanism of calcification: inhibitory role of pyrophosphate. Nature 195, 911 (1962).
Villa-Bellosta, R. & O’Neill, W. C. Pyrophosphate deficiency in vascular calcification. Kidney Int. 93, 1293–1297 (2018).
Liu, Y. et al. Progressive renal papillary calcification and ureteral stone formation in mice deficient for Tamm-Horsfall protein. Am. J. Physiol. Renal. Physiol. 299, F469–F478 (2010).
Wesson, J. A. et al. Osteopontin is a critical inhibitor of calcium oxalate crystal formation and retention in renal tubules. J. Am. Soc. Nephrol. 14, 139–147 (2003).
Khan, S. R. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol. Res. 40, 95–112 (2012).
Krohn, J. B., Hutcheson, J. D., Martinez-Martinez, E. & Aikawa, E. Extracellular vesicles in cardiovascular calcification: expanding current paradigms. J. Physiol. 594, 2895–2903 (2016).
Zazzeroni, L., Faggioli, G. & Pasquinelli, G. Mechanisms of arterial calcification: the role of matrix vesicles. Eur. J. Vasc. Endovasc. Surg. 55, 425–432 (2018).
Evan, A. P. et al. Apatite plaque particles in inner medulla of kidneys of calcium oxalate stone formers: osteopontin localization. Kidney Int. 68, 145–154 (2005).
Merchant, M. L. et al. Proteomic analysis of renal calculi indicates an important role for inflammatory processes in calcium stone formation. Am. J. Physiol. Renal Physiol. 295, F1254–F1258 (2008).
Canales, B. K. et al. Proteome of human calcium kidney stones. Urology 76, 1017 e13–1017 e20 (2010).
Boonla, C. et al. Inflammatory and fibrotic proteins proteomically identified as key protein constituents in urine and stone matrix of patients with kidney calculi. Clin. Chim. Acta 429, 81–89 (2014).
Stoller, M. L., Meng, M. V., Abrahams, H. M. & Kane, J. P. The primary stone event: a new hypothesis involving a vascular etiology. J. Urol. 171, 1920–1924 (2004).
Chen, L. et al. Anatomically-specific intratubular and interstitial biominerals in the human renal medullo-papillary complex. PLoS One 12, e0187103 (2017).
Hsi, R. S., Ramaswamy, K., Ho, S. P. & Stoller, M. L. The origins of urinary stone disease: upstream mineral formations initiate downstream Randall’s plaque. BJU Int. 119, 177–184 (2017).
Wiener, S. V. et al. Novel insights into renal mineralization and stone formation through advanced imaging modalities. Connect. Tissue Res. 59, 102–110 (2018).
Hsi, R. S. et al. Coronary artery calcium score and association with recurrent nephrolithiasis: the multi-ethnic study of atherosclerosis. J. Urol. 195, 971–976 (2016).
Reiner, A. P. et al. Kidney stones and subclinical atherosclerosis in young adults: the CARDIA study. J. Urol. 185, 920–925 (2011).
Masterson, J. H. et al. Dyslipidemia is associated with an increased risk of nephrolithiasis. Urolithiasis 43, 49–53 (2015).
Khan, S. R. & Glenton, P. A. Increased urinary excretion of lipids by patients with kidney stones. Br. J. Urol. 77, 506–511 (1996).
Sur, R. L. et al. Impact of statins on nephrolithiasis in hyperlipidemic patients: a 10-year review of an equal access health care system. Clin. Nephrol. 79, 351–355 (2012).
Wahl, P., Ducasa, G. M. & Fornoni, A. Systemic and renal lipids in kidney disease development and progression. Am. J. Physiol. Renal Physiol. 310, F433–F445 (2016).
Tesfamariam, B. The effects of HMG-CoA reductase inhibitors on endothelial function. Am. J. Cardiovasc. Drugs 6, 115–120 (2006).
Cohen, A. J. et al. Impact of statin intake on kidney stone formation. Urology 124, 57–61 (2019).
Cappuccio, F. P. et al. A prospective study of hypertension and the incidence of kidney stones in men. J. Hypertens. 17, 1017–1022 (1999).
Lopes, H. F. et al. DASH diet lowers blood pressure and lipid-induced oxidative stress in obesity. Hypertension 41, 422–430 (2003).
Taylor, E. N., Fung, T. T. & Curhan, G. C. DASH-style diet associates with reduced risk for kidney stones. J. Am. Soc. Nephrol. 20, 2253–2259 (2009).
Umekawa, T., Hatanaka, Y., Kurita, T. & Khan, S. R. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J. Am. Soc. Nephrol. 15, 635–644 (2004).
Joshi, S., Saylor, B. T., Wang, W., Peck, A. B. & Khan, S. R. Apocynin-treatment reverses hyperoxaluria induced changes in NADPH oxidase system expression in rat kidneys: a transcriptional study. PLoS One 7, e47738 (2012).
Kohri, K. et al. Biomolecular mechanism of urinary stone formation involving osteopontin. Urol. Res. 40, 623–637 (2012).
Khan, S. R. Reactive oxygen species, inflammation and calcium oxalate nephrolithiasis. Transl. Androl. Urol. 3, 256–276 (2014).
Joshi, S., Wang, W., Peck, A. B. & Khan, S. R. Activation of the NLRP3 inflammasome in association with calcium oxalate crystal induced reactive oxygen species in kidneys. J. Urol. 193, 1684–1691 (2015).
Schwille, P. O., Manoharan, M. & Schmiedl, A. Is idiopathic recurrent calcium urolithiasis in males a cellular disease? Laboratory findings in plasma, urine and erythrocytes, emphasizing the absence and presence of stones, oxidative and mineral metabolism: an observational study. Clin. Chem. Lab. Med. 43, 590–600 (2005).
Holoch, P. A. & Tracy, C. R. Antioxidants and self-reported history of kidney stones: the National Health and Nutrition Examination Survey. J. Endourol. 25, 1903–1908 (2011).
Grewal, J. S., Tsai, J. Y. & Khan, S. R. Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem. J. 387, 609–616 (2005).
Okada, A. et al. Renal macrophage migration and crystal phagocytosis via inflammatory-related gene expression during kidney stone formation and elimination in mice: detection by association analysis of stone-related gene expression and microstructural observation. J. Bone Miner. Res. 25, 2701–2711 (2010).
Khan, A., Wang, W. & Khan, S. R. Calcium oxalate nephrolithiasis and expression of matrix GLA protein in the kidneys. World J. Urol. 32, 123–130 (2014).
Khan, S. R. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin. Exp. Nephrol. 8, 75–88 (2004).
Umekawa, T., Byer, K., Uemura, H. & Khan, S. R. Diphenyleneiodium (DPI) reduces oxalate ion- and calcium oxalate monohydrate and brushite crystal-induced upregulation of MCP-1 in NRK 52E cells. Nephrol. Dial. Transplant. 20, 870–878 (2005).
Shroff, R. C. & Shanahan, C. M. The vascular biology of calcification. Semin. Dial. 20, 103–109 (2007).
Schurgers, L. J., Cranenburg, E. C. & Vermeer, C. Matrix Gla-protein: the calcification inhibitor in need of vitamin K. Thromb. Haemost. 100, 593–603 (2008).
Shanahan, C. M., Proudfoot, D., Farzaneh-Far, A. & Weissberg, P. L. The role of Gla proteins in vascular calcification. Crit.Rev. Eukaryot. Gene Expr. 8, 357–375 (1998).
Price, P. A., Urist, M. R. & Otawara, Y. Matrix Gla protein, a new gamma-carboxyglutamic acid-containing protein which is associated with the organic matrix of bone. Biochem. Biophys. Res. Commun. 117, 765–771 (1983).
Fraser, J. D. & Price, P. A. Lung, heart, and kidney express high levels of mRNA for the vitamin K-dependent matrix Gla protein. Implications for the possible functions of matrix Gla protein and for the tissue distribution of the gamma-carboxylase. J. Biol. Chem. 263, 11033–11036 (1988).
Gourgas, O., Marulanda, J., Zhang, P., Murshed, M. & Cerruti, M. Multidisciplinary approach to understand medial arterial calcification. Arterioscler. Thromb. Vasc. Biol. 38, 363–372 (2018).
Gao, B. et al. A polymorphism of matrix Gla protein gene is associated with kidney stones. J. Urol. 177, 2361–2365 (2007).
Lu, X. et al. A polymorphism of matrix Gla protein gene is associated with kidney stone in the Chinese Han population. Gene 511, 127–130 (2012).
Wang, Q. et al. High concentration of calcium promotes mineralization in NRK-52E cells via inhibiting the expression of matrix gla protein. Urology 119, 161 e1–161 e7 (2018).
Jahnen-Dechent, W., Schafer, C., Ketteler, M. & McKee, M. D. Mineral chaperones: a role for fetuin-A and osteopontin in the inhibition and regression of pathologic calcification. J. Mol. Med. 86, 379–389 (2008).
Moe, S. M. et al. Role of calcification inhibitors in the pathogenesis of vascular calcification in chronic kidney disease (CKD). Kidney Int. 67, 2295–2304 (2005).
Schinke, T. et al. The serum protein alpha2-HS glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A possible role in mineralization and calcium homeostasis. J. Biol. Chem. 271, 20789–20796 (1996).
Ketteler, M. et al. Deficiencies of calcium-regulatory proteins in dialysis patients: a novel concept of cardiovascular calcification in uremia. Kidney Int. Suppl. 63, S84–S87 (2003).
Ford, M. L., Tomlinson, L. A., Chapman, T. P., Rajkumar, C. & Holt, S. G. Aortic stiffness is independently associated with rate of renal function decline in chronic kidney disease stages 3 and 4. Hypertension 55, 1110–1115 (2010).
Mehrsai, A., Guitynavard, F., Nikoobakht, M. R., Gooran, S. & Ahmadi, A. The relationship between serum and urinary Fetuin-A levels and kidney stone formation among kidney stone patients. Cent. European J. Urol. 70, 394–399 (2017).
Liberman, M. & Marti, L. C. Vascular calcification regulation by exosomes in the vascular wall. Adv. Exp. Med. Biol. 998, 151–160 (2017).
Heiss, A. et al. Structural basis of calcification inhibition by α2-HS glycoprotein/fetuin-A. Formation of colloidal calciprotein particles. J. Biol. Chem. 278, 13333–13341 (2003).
Holt, S. G. & Smith, E. R. Fetuin-A-containing calciprotein particles in mineral trafficking and vascular disease. Nephrol. Dial. Transplant. 31, 1583–1587 (2016).
Okumura, N. et al. Diversity in protein profiles of individual calcium oxalate kidney stones. PLoS One 8, e68624 (2013).
Taguchi, K. et al. Genome-wide gene expression profiling of Randall’s plaques in calcium oxalate stone formers. J. Am. Soc. Nephrol. 28, 333–347 (2017).
Sun, A. Y. et al. Inflammatory cytokines in the papillary tips and urine of nephrolithiasis patients. J. Endourol. 32, 236–244 (2018).
Taguchi, K. et al. M1/M2-macrophage phenotypes regulate renal calcium oxalate crystal development. Sci. Rep. 6, 35167 (2016).
Xi, J. et al. Sirtuin 3 suppresses the formation of renal calcium oxalate crystals through promoting M2 polarization of macrophages. J. Cell Physiol. 234, 11463–11473 (2019).
Kovacevic, L., Lu, H., Caruso, J. A., Kovacevic, N. & Lakshmanan, Y. Urinary proteomics reveals association between pediatric nephrolithiasis and cardiovascular disease. Int. Urol. Nephrol. 50, 1949–1954 (2018).
Kusumi, K. et al. Adolescents with urinary stones have elevated urine levels of inflammatory mediators. Urolithiasis 47, 461–466 (2019).
Tang, P. M., Nikolic-Paterson, D. J. & Lan, H. Y. Macrophages: versatile players in renal inflammation and fibrosis. Nat. Rev. Nephrol. 15, 144–158 (2019).
Kusmartsev, S. et al. Calcium oxalate stone fragment and crystal phagocytosis by human macrophages. J. Urol. 195, 1143–1151 (2016).
Umekawa, T., Chegini, N. & Khan, S. R. Increased expression of monocyte chemoattractant protein-1 (MCP-1) by renal epithelial cells in culture on exposure to calcium oxalate, phosphate and uric acid crystals. Nephrol. Dial. Transplant. 18, 664–669 (2003).
Dominguez-Gutierrez, P. R., Kusmartsev, S., Canales, B. K. & Khan, S. R. Calcium oxalate differentiates human monocytes into inflammatory M1 macrophages. Front. Immunol. 9, 1863 (2018).
Taguchi, K. et al. Colony-stimulating factor-1 signaling suppresses renal crystal formation. J. Am. Soc. Nephrol. 25, 1680–1697 (2014).
Anders, H. J. et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 93, 656–669 (2018).
Zhu, W. et al. Loss of the androgen receptor suppresses intrarenal calcium oxalate crystals deposition via altering macrophage recruitment/M2 polarization with change of the miR-185-5p/CSF-1 signals. Cell Death Dis. 10, 275 (2019).
Khan, S. R. & Thamilselvan, S. Nephrolithiasis: a consequence of renal epithelial cell exposure to oxalate and calcium oxalate crystals. Mol. Urol. 4, 305–312 (2000).
Okada, A. et al. Successful formation of calcium oxalate crystal deposition in mouse kidney by intraabdominal glyoxylate injection. Urol. Res. 35, 89–99 (2007).
de Water, R. et al. Calcium oxalate nephrolithiasis: effect of renal crystal deposition on the cellular composition of the renal interstitium. Am. J. Kidney Dis. 33, 761–771 (1999).
Khan, S. R. et al. Crystal-cell interaction and apoptosis in oxalate-associated injury of renal epithelial cells. J. Am. Soc. Nephrol. 10, 457–463 (1999).
de Bruijn, W. C. et al. Etiology of calcium oxalate nephrolithiasis in rats. I. Can this be a model for human stone formation? Scanning Microsc. 9, 103–114 (1995).
Canton, J., Khezri, R., Glogauer, M. & Grinstein, S. Contrasting phagosome pH regulation and maturation in human M1 and M2 macrophages. Mol. Biol. Cell. 25, 3330–3341 (2014).
Zuo, J., Khan, A., Glenton, P. A. & Khan, S. R. Effect of NADPH oxidase inhibition on the expression of kidney injury molecule and calcium oxalate crystal deposition in hydroxy-L-proline-induced hyperoxaluria in the male Sprague–Dawley rats. Nephrol. Dial. Transplant. 26, 1785–1796 (2011).
Joshi, S., Wang, W. & Khan, S. R. Transcriptional study of hyperoxaluria and calcium oxalate nephrolithiasis in male rats: inflammatory changes are mainly associated with crystal deposition. PLoS One 12, e0185009 (2017).
Joshi, G. N., Goetjen, A. M. & Knecht, D. A. Silica particles cause NADPH oxidase-independent ROS generation and transient phagolysosomal leakage. Mol. Biol. Cell. 26, 3150–3164 (2015).
Shanahan, C. M., Crouthamel, M. H., Kapustin, A. & Giachelli, C. M. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ. Res. 109, 697–711 (2011).
Murshed, M. & McKee, M. D. Molecular determinants of extracellular matrix mineralization in bone and blood vessels. Curr. Opin. Nephrol. Hypertens. 19, 359–365 (2010).
Golub, E. E. Biomineralization and matrix vesicles in biology and pathology. Semin. Immunopathol. 33, 409–417 (2010).
Fasano, J. M. & Khan, S. R. Intratubular crystallization of calcium oxalate in the presence of membrane vesicles: an in vitro study. Kidney Int. 59, 169–178 (2001).
Khan, S. R., Glenton, P. A., Backov, R. & Talham, D. R. Presence of lipids in urine, crystals and stones: implications for the formation of kidney stones. Kidney Int. 62, 2062–2072 (2002).
Khan, S. R. & Canales, B. K. Ultrastructural investigation of crystal deposits in Npt2a knockout mice: are they similar to human Randall’s plaques? J. Urol. 186, 1107–1113 (2011).
Khan, S. R. et al. Lipids and membranes in the organic matrix of urinary calcific crystals and stones. Calcif. Tissue Int. 59, 357–365 (1996).
Khan, S. R., Shevock, P. N. & Hackett, R. L. Presence of lipids in urinary stones: results of preliminary studies. Calcif. Tissue Int. 42, 91–96 (1988).
Skotland, T., Hessvik, N. P., Sandvig, K. & Llorente, A. Exosomal lipid composition and the role of ether lipids and phosphoinositides in exosome biology. J. Lipid. Res. 60, 9–18 (2019).
Joshi, S., Clapp, W. L., Wang, W. & Khan, S. R. Osteogenic changes in kidneys of hyperoxaluric rats. Biochim. Biophys. Acta 1852, 2000–2012 (2015).
Khan, S. R., Joshi, S. & Wang, W. Dedifferentiation of renal epithelial cells into osteogenic cells and formation of Randall’s plaque. J. Am. Soc. Nephrol. 25, 101A (2014).
Hunter, G. K. Role of osteopontin in modulation of hydroxyapatite formation. Calcif. Tissue Int. 93, 348–354 (2013).
Liu, T. M. & Lee, E. H. Transcriptional regulatory cascades in Runx2-dependent bone development. Tissue Eng. B Rev. 19, 254–263 (2013).
Liu, W. et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J. Cell. Biol. 155, 157–166 (2001).
Matsubara, T. et al. BMP2 regulates Osterix through Msx2 and Runx2 during osteoblast differentiation. J. Biol. Chem. 283, 29119–29125 (2008).
Lomashvili, K. A., Garg, P., Narisawa, S., Millan, J. L. & O’Neill, W. C. Upregulation of alkaline phosphatase and pyrophosphate hydrolysis: potential mechanism for uremic vascular calcification. Kidney Int. 73, 1024–1030 (2008).
Okada, A. et al. Genome-wide analysis of genes related to kidney stone formation and elimination in the calcium oxalate nephrolithiasis model mouse: detection of stone-preventive factors and involvement of macrophage activity. J. Bone Miner. Res. 24, 908–924 (2009).
Thiery, J. P. & Sleeman, J. P. Complex networks orchestrate epithelial-mesenchymal transitions. Nat. Rev. Mol. Cell. Biol. 7, 131–142 (2006).
Jia, Z. et al. Does crystal deposition in genetic hypercalciuric rat kidney tissue share similarities with bone formation? Urology 83, 509 e7–509 14 (2014).
Jia, Z. et al. Role of calcium in the regulation of bone morphogenetic protein 2, Runt-related transcription factor 2 and Osterix in primary renal tubular epithelial cells by the vitamin D receptor. Mol. Med. Rep. 12, 2082–2088 (2015).
Convento, M., Pessoa, E., Aragao, A., Schor, N. & Borges, F. Oxalate induces type II epithelial to mesenchymal transition (EMT) in inner medullary collecting duct cells (IMCD) in vitro and stimulate the expression of osteogenic and fibrotic markers in kidney medulla in vivo. Oncotarget 10, 1102–1118 (2019).
Miyazawa, K., Aihara, K., Ikeda, R., Moriyama, M. T. & Suzuki, K. cDNA macroarray analysis of genes in renal epithelial cells exposed to calcium oxalate crystals. Urol. Res. 37, 27–33 (2009).
Mezzabotta, F. et al. Spontaneous calcification process in primary renal cells from a medullary sponge kidney patient harbouring a GDNF mutation. J. Cell. Mol. Med. 19, 889–902 (2015).
Evan, A. P. et al. Biopsy proven medullary sponge kidney: clinical findings, histopathology, and role of osteogenesis in stone and plaque formation. Anat. Rec. 298, 865–877 (2015).
Khan, S. R. & Gambaro, G. Role of osteogenesis in the formation of Randall’s plaques. Anat. Rec. 299, 5–7 (2016).
Collett, G. D. & Canfield, A. E. Angiogenesis and pericytes in the initiation of ectopic calcification. Circ. Res. 96, 930–938 (2005).
Doherty, M. J. et al. Vascular pericytes express osteogenic potential in vitro and in vivo. J. Bone Miner. Res. 13, 828–838 (1998).
Cola, C., Almeida, M., Li, D., Romeo, F. & Mehta, J. L. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem. Biophys. Res. Commun. 320, 424–427 (2004).
Sarica, K., Aydin, H., Yencilek, F., Telci, D. & Yilmaz, B. Human umbilical vein endothelial cells accelerate oxalate-induced apoptosis of human renal proximal tubule epithelial cells in co-culture system which is prevented by pyrrolidine dithiocarbamate. Urol. Res. 40, 461–466 (2012).
Priante, G. et al. Human proximal tubular cells can form calcium phosphate deposits in osteogenic culture: role of cell death and osteoblast-like transdifferentiation. Cell Death Discov. 5, 57 (2019).
Chinetti-Gbaguidi, G. et al. Human alternative macrophages populate calcified areas of atherosclerotic lesions and display impaired RANKL-induced osteoclastic bone resorption activity. Circ. Res. 121, 19–30 (2017).
Rogers, M. A., Aikawa, M. & Aikawa, E. Macrophage heterogeneity complicates reversal of calcification in cardiovascular tissues. Circ. Res. 121, 5–7 (2017).
Bushinsky, D. A., Frick, K. K. & Nehrke, K. Genetic hypercalciuric stone-forming rats. Curr. Opin. Nephrol. Hypertens. 15, 403–418 (2006).
Agharazii, M. et al. Inflammatory cytokines and reactive oxygen species as mediators of chronic kidney disease-related vascular calcification. Am. J. Hypertens. 28, 746–755 (2015).
Byon, C. H. et al. Oxidative stress induces vascular calcification through modulation of the osteogenic transcription factor Runx2 by AKT signaling. J. Biol. Chem. 283, 15319–15327 (2008).
Khan, S. R. Reactive oxygen species as the molecular modulators of calcium oxalate kidney stone formation: evidence from clinical and experimental investigations. J. Urol. 189, 803–811 (2013).
Khan, S. R., Joshi, S., Wang, W. & Peck, A. B. Regulation of macromolecular modulators of urinary stone formation by reactive oxygen species: transcriptional study in an animal model of hyperoxaluria. Am. J. Physiol. Renal Physiol. 306, F1285–F1295 (2014).
Wen, C. et al. Nalp3 inflammasome is activated and required for vascular smooth muscle cell calcification. Int. J. Cardiol. 168, 2242–2247 (2013).
Chen, T. C. et al. The antagonism of 6-shogaol in high-glucose-activated NLRP3 inflammasome and consequent calcification of human artery smooth muscle cells. Cell Biosci. 10, 5 (2020).
Jono, S. et al. Phosphate regulation of vascular smooth muscle cell calcification. Circ. Res. 87, E10–E17 (2000).
Jono, S., Shioi, A., Ikari, Y. & Nishizawa, Y. Vascular calcification in chronic kidney disease. J. Bone Miner. Metab. 24, 176–181 (2006).
Kapustin, A. N. et al. Calcium regulates key components of vascular smooth muscle cell-derived matrix vesicles to enhance mineralization. Circ. Res. 109, e1–e12 (2011).
Kapustin, A. N. & Shanahan, C. M. Calcium regulation of vascular smooth muscle cell-derived matrix vesicles. Trends Cardiovasc. Med. 22, 133–137 (2012).
Gambaro, G. et al. Crystals, Randall’s plaques and renal stones: do bone and atherosclerosis teach us something? J. Nephrol. 17, 774–777 (2004).
Zhu, F., Friedman, M. S., Luo, W., Woolf, P. & Hankenson, K. D. The transcription factor Osterix (SP7) regulates BMP6-induced human osteoblast differentiation. J. Cell. Physiol. 227, 2677–2685 (2012).
Durham, A. L., Speer, M. Y., Scatena, M., Giachelli, C. M. & Shanahan, C. M. Role of smooth muscle cells in vascular calcification: implications in atherosclerosis and arterial stiffness. Cardiovasc. Res. 114, 590–600 (2018).
Shroff, R. C. et al. The circulating calcification inhibitors, fetuin-A and osteoprotegerin, but not matrix Gla protein, are associated with vascular stiffness and calcification in children on dialysis. Nephrol. Dial. Transplant. 23, 3263–3271 (2008).
Kapustin, A. N. & Shanahan, C. M. Osteocalcin: a novel vascular metabolic and osteoinductive factor? Arterioscler. Thromb. Vasc. Biol. 31, 2169–2171 (2011).
Shanahan, C. M. et al. Expression of mineralisation-regulating proteins in association with human vascular calcification. Z. Kardiol. 89, 63–68 (2000).
Shanahan, C. M. Vascular calcification. Curr. Opin. Nephrol. Hypertens. 14, 361–367 (2005).
Shioi, A. & Ikari, Y. Plaque calcification during atherosclerosis progression and regression. J. Atheroscler. Thromb. 25, 294–303 (2018).
Cho, K. I., Sakuma, I., Sohn, I. S., Jo, S. H. & Koh, K. K. Inflammatory and metabolic mechanisms underlying the calcific aortic valve disease. Atherosclerosis 277, 60–65 (2018).
Li, G. et al. The shift of macrophages toward M1 phenotype promotes aortic valvular calcification. J. Thorac. Cardiovasc. Surg. 153, 1318–1327 e1 (2017).
Anderson, L. & Mc, D. J. The origin, frequency, and significance of microscopic calculi in the kidney. Surg. Gynecol. Obstet. 82, 275–282 (1946).
Roberts, S. D. & Resnick, M. I. Glycosaminoglycans content of stone matrix. J. Urol. 135, 1078–1083 (1986).
Talham, D. R. et al. Role of lipids in urinary stones: studies of calcium oxalate precipitation at phospholipid langmuir monolayers. Langmuir 22, 2450–2456 (2006).
Nishio, S. et al. Matrix glycosaminoglycan in urinary stones. J. Urol. 134, 503–505 (1985).
Author information
Authors and Affiliations
Contributions
S.R.K. and P.R.D.-G. researched data for the article. All authors made substantial contributions to discussions of the content, wrote the manuscript, and reviewed or edited the manuscript before submission.
Corresponding author
Ethics declarations
Competing interests
B.K.C. receives grant support through Alnylam Pharmaceuticals and the National Institutes of Health, is paid for his services on the AUA Content Review Committee and has ownership/stock options with AP LifeSciences and ForTec Litho, LLC. The other authors declare no competing interests.
Additional information
Peer review information
Nature Reviews Nephrology thanks E. Worcester, T. Yasui and the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Glossary
- Lithogenic
-
Mineralization-inducing.
- Concretions
-
Masses formed by the accumulation and aggregation of crystals.
- Ectopic mineralization
-
A pathological biomineralization that occurs in soft tissue and generally involves the deposition of calcium phosphate.
- Matrix vesicles
-
Small, membrane-bound and mostly spherical bodies present at mineralization sites.
- Crystal nucleation
-
The first step of crystal formation in which ions reorganize to form a solid phase.
- Transwell culture system
-
Culture system with two chambers separated by a permeable membrane that is used to investigate the role of soluble mediators in interactions between cells.
- Giant cells
-
Multinucleated cells formed by the fusion of several distinct cells such as macrophages.
- Medullary sponge kidney
-
A rare congenital kidney disorder in which small cysts form in the kidney tubules.
Rights and permissions
About this article
Cite this article
Khan, S.R., Canales, B.K. & Dominguez-Gutierrez, P.R. Randall’s plaque and calcium oxalate stone formation: role for immunity and inflammation. Nat Rev Nephrol 17, 417–433 (2021). https://doi.org/10.1038/s41581-020-00392-1
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41581-020-00392-1
This article is cited by
-
The association between C-reactive protein levels and the risk of kidney stones: a population-based study
BMC Nephrology (2024)
-
Association between drinking status and risk of kidney stones among United States adults: NHANES 2007–2018
BMC Public Health (2024)
-
Exosomal mediators in sepsis and inflammatory organ injury: unraveling the role of exosomes in intercellular crosstalk and organ dysfunction
Military Medical Research (2024)
-
Association of serum soluble α‑klotho with risk of kidney stone disease: a population-based cross-sectional study
World Journal of Urology (2024)
-
Identification of biomarkers and potential therapeutic targets of kidney stone disease using bioinformatics
World Journal of Urology (2024)